Fineline Cube

Follow:
14778 Articles
Dizal Pharmaceutical's Sunvozertinib Earns Breakthrough Designation for NSCLC from China's NMPA
CompanyDrug

Dizal Pharmaceutical’s Sunvozertinib Earns Breakthrough Designation for NSCLC from China’s NMPA

NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures
Policy / Regulatory

NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures

Huawei Partners with Medical University Hospital to Boost Healthcare Innovation
CompanyDeals

Huawei Partners with Medical University Hospital to Boost Healthcare Innovation

Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment
CompanyDrug

Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment

Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest
CompanyDeals

Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest

Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study
CompanyDrug

Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study

Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
CompanyDrug

Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment

Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study
CompanyDrug

Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study

Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing
Company

Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing

CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment
CompanyDrug

CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment

KangaBio's KGX101 Receives NMPA Approval for Clinical Trial in China
CompanyDrug

KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials
Drug

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials